caa a22 4500 465790070 CHVBK 20180323112021.0 cr unu---uuuuu 170327e19900501xx s 000 0 eng 10.1007/BF00177252 doi (NATIONALLICENCE)springer-10.1007/BF00177252 Phase I evaluation of diaziquone in childhood cancer [Elektronische Daten] A Pediatric Oncology Group study [J. Falletta, B. Cushing, S. Lauer, B. Bell, D. Mahoney, R. Castleberry, R. Krance] Summary: We conducted a phase I clinical study of aziridinylbenzoquinone (Diaziquone, AZQ) given as a 4 hour infusion weekly × 4. Forty-five children with recurrent acute leukemia and 33 children with various advanced solid tumors participated. Severe myelosuppression was the dose limiting toxic effect, occurring in all patients at the upper dose levels. Gastrointestinal and hepatic toxicities were infrequent and not severe. No allergic reactions occurred. Objective tumor regression was noted in 3 of 25 patients with a CNS tumor and in 6 of 45 patients with acute leukemia. For phase II trials the recommended dosage of Diaziquone given by this schedule is 18 mg/M2×4 for patients with a solid tumor, and is 30 mg/M2/week × 4 for children with acute leukemia. Kluwer Academic Publishers, 1990 diaziquone nationallicence childhood malignancies nationallicence chemotherapy nationallicence Falletta J. Duke University Medical Center, Durham, NC, USA aut Cushing B. Children's Hospital of Michigan, Detroit, MI, USA aut Lauer S. Medical College of Wisconsin, Milwaukee, WI, USA aut Bell B. Emory University School of Medicine, Atlanta, GA, USA aut Mahoney D. Baylor College of Medicine, Houston, TX, USA aut Castleberry R. University of Alabama School of Medicine, Birmingham, AL, USA aut Krance R. City of Hope National Medical Center, Duarte, CA, USA aut Investigational New Drugs Kluwer Academic Publishers 8/2(1990-05-01), 167-170 0167-6997 8:2<167 1990 8 10637 https://doi.org/10.1007/BF00177252 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00177252 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Falletta J. Duke University Medical Center, Durham, NC, USA aut NATIONALLICENCE 700 1- Cushing B. Children's Hospital of Michigan, Detroit, MI, USA aut NATIONALLICENCE 700 1- Lauer S. Medical College of Wisconsin, Milwaukee, WI, USA aut NATIONALLICENCE 700 1- Bell B. Emory University School of Medicine, Atlanta, GA, USA aut NATIONALLICENCE 700 1- Mahoney D. Baylor College of Medicine, Houston, TX, USA aut NATIONALLICENCE 700 1- Castleberry R. University of Alabama School of Medicine, Birmingham, AL, USA aut NATIONALLICENCE 700 1- Krance R. City of Hope National Medical Center, Duarte, CA, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/2(1990-05-01), 167-170 0167-6997 8:2<167 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer